- Find our latest Case Studies
- Our Platforms
Platform 1: Bioactives Library
Designed to drive innovation and support companies of all sizes on the discovery journey, this platform offers industry early access to one of the world’s largest and most diverse, and completely novel Bioactives Libraries, developed by the Liverpool School of Tropical Medicine.
This vast, untapped pool of thousands of environmental, bacterial, and fungal isolates has the potential to shape the next generation of transformative novel antimicrobial products and therapies.
The library is designed in a modular format to improve usability and increase efficiency. This enables a targeted approach, where specific isolate groups can be screened quickly and cost-efficiently. World-class end-to-end expertise and after-care from the expert team at LSTM ensures companies are supported at every stage of the discovery journey.
Expert antimicrobial product development support, validation, and consultancy is also available to industry partners at the early stage of the product development journey.
For more information or to learn how your business can engage with this platform.
Platform Lead
Professor Adam Roberts
Professor, Antimicrobial Chemotherapy and Resistance, Liverpool School of Tropical Medicine
Professor Adam Roberts
Professor, Antimicrobial Chemotherapy and Resistance, Liverpool School of Tropical Medicine
Adam Roberts is a Professor and AMR lead at the Liverpool School of Tropical Medicine. Adam has been investigating the fundamental mechanisms of transferable AMR for more than 20 years and, since arriving at Liverpool School of Tropical Medicine in 2017, has focussed on translational aspects of AMR and early-stage drug discovery and development.
His current research activities include investigations into the many drivers of resistance in a One Health context, the molecular genetics of resistance mechanisms and mobile genetic elements and how they contribute to the dissemination of AMR and the use of evolutionary biology to inform antibiotic treatment regimens and drug design. His team also carry out discovery projects, investigating novel antimicrobial natural products, target-site identification, mechanism of action, and determining the resistance development potential of novel molecules within the LSTM’s drug development pipeline.
Adam’s research activities have led to more than 100 peer reviewed publications and reviews on AMR and his group is currently funded by the Medical Research Council, the National Institute for Health Research, UK Research and Innovation’s Strength in Places Fund, and the European Regional Development Fund plus various charities including the Wellcome Trust and the Medical Research Foundation. He runs The Transposon Registry and the award-winning citizen-science, drug-discovery project Swab and Send, is the Network coordinator of the JPIAMR Network of European and African Researchers on AMR (NEAR-AMR) and is a policy advisor (Drug Resistance) to the Royal Society of Tropical Medicine and Hygiene.
